Breast cancer : A New Triple Therapy for Aggressive Metastatic Breast Cancers

Another academic trial conducted by Institut Curie will be presented at ASCO: the TUC-TOC Phase 2 study to evaluate a new combination therapy in approximately 60 patients with HER2+ metastatic breast cancer. This approach combines targeted therapy, an anti-HER2 antibody and oral chemotherapy in order to extend the possibilities of patient management at an advanced stage of the disease. Coordinated by Dr. Diana Bello Roufai and Dr. Florence Lerebours,, medical oncologists at Institut Curie, TUC-TOC offers an alternative to patients in advanced situations, when standard third-line treatments are no longer effective. 

"In these advanced situations, it is crucial to expand the range of treatments and to be able to develop effective treatment options that are well tolerated, easily administered and accessible for patients ", emphasizes Dr. Diana Bello Roufai.